Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Advertising and Sponsorship
    • Profile & Readership
    • Contact Us
    • Latest News
    • Privacy & Cookies Policies
    • Terms of Use
    • Advertising Terms
    • Issue 81
    • Issue 80
    • Issue 79
    • Issue 78
    • Issue 77
    • Issue 76
    • Issue 75
    • Issue 74
    • Issue 73
    • Issue 72
    • Issue 71
    • Issue 70
    • View All
    • About the Awards
    • Awards Timetable
    • Awards Winners
    • Submit Nominations
    • Testimonials
    • Media Room
    • FAQ
    • Asset Management Awards
    • Brand of the Year Awards
    • Business Awards
    • Cash Management Banking Awards
    • Banking Technology Awards
    • CEO Awards
    • Customer Service Awards
    • CSR Awards
    • Deal of the Year Awards
    • Corporate Governance Awards
    • Corporate Banking Awards
    • Digital Transformation Awards
    • Fintech Awards
    • Education & Training Awards
    • ESG & Sustainability Awards
    • ESG Awards
    • Forex Banking Awards
    • Innovation Awards
    • Insurance & Takaful Awards
    • Investment Banking Awards
    • Investor Relations Awards
    • Leadership Awards
    • Islamic Banking Awards
    • Real Estate Awards
    • Project Finance Awards
    • Process & Product Awards
    • Telecommunication Awards
    • HR & Recruitment Awards
    • Trade Finance Awards
    • The Next 100 Global Awards
    • Wealth Management Awards
    • Travel Awards
    • Years of Excellence Awards
    • Publishing Principles
    • Ownership & Funding
    • Corrections Policy
    • Editorial Code of Ethics
    • Diversity & Inclusion Policy
    • Fact Checking Policy
    Original content: Global Banking and Finance Review - https://www.globalbankingandfinance.com

    A global financial intelligence and recognition platform delivering authoritative insights, data-driven analysis, and institutional benchmarking across Banking, Capital Markets, Investment, Technology, and Financial Infrastructure.

    Copyright © 2010-2026 - All Rights Reserved. | Sitemap | Tags

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    1. Home
    2. >Finance
    3. >Novo reports first Ozempic sales drop in greater China region
    Finance

    Novo Reports First Ozempic Sales Drop in Greater China Region

    Published by Global Banking & Finance Review®

    Posted on February 5, 2026

    2 min read

    Last updated: February 5, 2026

    Add as preferred source on Google
    Novo reports first Ozempic sales drop in greater China region - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:innovationfinancial communitymarket capitalisation

    Quick Summary

    Novo Nordisk's Ozempic sales in China fell for the first time due to competition and price pressures, impacting earnings.

    Novo Nordisk Sees First Decline in Ozempic Sales in Greater China

    Ozempic Sales Performance in Greater China

    By Andrew Silver

    Market Competition and New Approvals

    SHANGHAI, Feb 5 (Reuters) - Sales of Novo Nordisk's blockbuster diabetes drug Ozempic in the greater China region fell for the first time last year, as it grapples with competition from rivals.

    Impact on Novo Nordisk's Earnings

    The sales drop underscores a bleak outlook from the Danish diabetes drug giant which shocked the market this week by flagging a potential earnings drop, ending years of double-digit gains, due to "unprecedented" price pressures.

    Sales of Ozempic injector pens in mainland China, Taiwan and Hong Kong - Novo's largest market after the U.S. - slipped 7% to about 5.4 billion Danish crowns ($853 million) in 2025.

    Ozempic first won approval from China in 2021 and had until last year only had sales gains there, the company's annual reports show.

    But China has since approved similar drugs including Eli Lilly's Mounjaro, Innovent Biologics' mazdutide and Guangzhou Innogen's efsubaglutide alfa.

    The Innogen and Lilly medicines were added to China's state-run health insurance scheme last month for patients with type 2 diabetes, joining Ozempic.

    Another Chinese drugmaker, Sciwind Biosciences, also said last month that its type 2 diabetes treatment Xianyida has been approved for use in the country.

    "We have a very strong market position with Ozempic, still low penetration, and I would say competition is more entering at this point in time," Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in an interview this week.

    The greater China region accounted for 14% of all 2025 sales in its international operations that exclude the U.S. market, according to a separate investor presentation.

    ($1 = 6.3339 Danish crowns)

    (Reporting by Andrew Silver in Shanghai; Additional reporting by Maggie Fick in London; Editing by Miyoung Kim and Edwina Gibbs)

    Table of Contents

    • Ozempic Sales Performance in Greater China
    • Market Competition and New Approvals
    • Impact on Novo Nordisk's Earnings

    Key Takeaways

    • •Novo Nordisk's Ozempic sales in China fell for the first time.
    • •Increased competition from Eli Lilly and Innovent Biologics.
    • •Ozempic sales dropped 7% to 5.4 billion Danish crowns.
    • •China's approval of similar drugs impacts market share.
    • •Potential earnings drop due to price pressures.

    Frequently Asked Questions about Novo reports first Ozempic sales drop in greater China region

    1What is market competition?

    Market competition refers to the rivalry among businesses to attract customers and increase sales. It can influence pricing, product offerings, and overall market dynamics.

    More from Finance

    Explore more articles in the Finance category

    Image for Spain's minister calls on power firms to make blackout information public
    Spain's Minister Calls on Power Firms to Make Blackout Information Public
    Image for OnlyFans owner Leonid Radvinsky dies of cancer at 43, Bloomberg News reports
    OnlyFans Owner Leonid Radvinsky Dies of Cancer at 43, Bloomberg News Reports
    Image for Freedom Holding Corp. Scales Operations Through Bank Acquisition in Turkey
    Freedom Holding Corp. Scales Operations Through Bank Acquisition in Turkey
    Image for EasyJet warns Iran war will push up ticket prices from end of summer
    EasyJet Warns Iran War Will Push up Ticket Prices From End of Summer
    Image for Putin calls for 'balanced decisions' on use of Russia's energy revenues
    Putin Calls for 'balanced Decisions' on Use of Russia's Energy Revenues
    Image for Ukraine has enough diesel for March, but April uncertain, says consultancy
    Ukraine Has Enough Diesel for March, but April Uncertain, Says Consultancy
    Image for UK counter-terror police leading probe into attack on Jewish community ambulances
    UK Counter-Terror Police Leading Probe Into Attack on Jewish Community Ambulances
    Image for FTSE 100 on correction course as Iran war boosts rate hike bets
    FTSE 100 on Correction Course as Iran War Boosts Rate Hike Bets
    Image for Oil falls over 13% on Trump postponing military strikes on Iran energy infrastructure
    Oil Falls Over 13% on Trump Postponing Military Strikes on Iran Energy Infrastructure
    Image for EU-Mercosur trade accord to apply provisionally from May 1
    EU-Mercosur Trade Accord to Apply Provisionally From May 1
    Image for Instant View: World markets rally as Trump postpones military strikes on Iranian power plants
    Instant View: World Markets Rally as Trump Postpones Military Strikes on Iranian Power Plants
    Image for German court rejects bid to ban Mercedes and BMW's fossil-fuel cars
    German Court Rejects Bid to Ban Mercedes and BMW's Fossil-Fuel Cars
    View All Finance Posts
    Previous Finance PostPandora Goes Platinum-Plated to Cut Reliance on Costly Silver
    Next Finance PostMaersk Flags 2026 Earnings Hit as Suez Return, Overcapacity Hit Freight Rates